Source: PR Newswire UK

Press Release: Bristol-Myers Squibb : Septa Pharmaceuticals Inc. Acquires CeeNU (Lomustine) from Bristol Myers Squibb, Canada

Mississauga, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic acquisition...

Read full article »
Annual Revenue
$10-50B
Employees
10-50K
Christopher Boerner's photo - CEO of Bristol-Myers Squibb

CEO

Christopher Boerner

CEO Approval Rating

61/100

Read more